Articles On ImpediMed (ASX:IPD)

ASX health sector falls 2.2% for the week as rotation back to sector loses momentum, while broader market up 0.2%  Cochlear backed Epiminder has a disappointing first week on the ASX after its IPO on Monday Mach7 signs a five-year subscrip...

Testing giant ALS has shrugged off weak drug testing revenues to post a 12% half-year profit boost, so it’s no ‘pharmageddon’ Tryptamine’s binge eating psychedelics trial kicks up a gear Impedimed eyes revenue beyond detecting lymphoedema...

Having satisfied the FDA about safety concerns, Neurizon will motor on to the Healey trial platform LTR Pharma invests $1 million in omega-3 side venture Thanks to options, 4D Medical cashes up   Neurizon Therapeutics (ASX:NUZ) is free to...

Impedimed and Avita Medical have won a ‘pay rise’ from private and public US payors Orthocell posts record revenue – an entrée perhaps, with US sales main course to come  Gut disorders house Immuron outlines a packed October schedule   Fe...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback  ‘Mostly pretty good’ June quarterly reporting season comes to end  Clarity Pharmaceuticals completes $203 million capital raise to institutional i...

ASX health stocks rally 5% over past five days as sector’s largest company CSL rises 6.3% Recruitment completed for a phase II investigator-led study of Clarity’s prostate cancer imaging agent EBR receives preliminary Transitional Pass-Thr...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((LTM)) - Arcad...

Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy (BIS) device for early detection and prevention of lymph...

Highlights Rapid sector growth offers new prospects for ASX-listed healthcare firms Key players (IPD,DXB,IMR) are enhancing regional presence Rising demand driven by innovation and demographic trends fuels market expansion The healthc...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

ASX health stocks fall 2.8% over past week, while the broader market rose 0.3%  Fisher & Paykel Healthcare could take hit by proposed new US tariffs on Mexico CSL among larger ASX health care names due to report half yearly results nex...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck By Rudi Filapek-Vandyck, Editor The February results season will soon...

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Medical technology company ImpediMed (ASX:IPD) continues to make strides with its SOZO® Digital Health Platform, reporting significant progress in its Q1 FY25 results. The company’s pipeline for SOZO units increased by 34%, with 28 units so...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

The ASX is anticipated to experience a slight decline at the opening on Tuesday, following Wall Street's gains as investors analyze comments from U.S. policymakers. At 8 AM AEST, the SPI ASX200 futures contract indicated a decrease of 0.1%....

ASX set for slight drop as investors digest Fed comments Fed officials hint at potential future rate cuts Gold prices hit record highs while Tesla and Boeing rise   The ASX is looking at a slight drop when the market opens on Tuesday desp...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

When I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lifting team performance was to replace the coach – a ploy that works about as often as it doesn’t. Back then, Rick Valencia had just replaced...

ASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power confident US Fed’s 50 basis points cut in cash rate this week will bring more optimism to the sector  Morgans, investor relations firm IR Dep...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Broker Rating Changes (Post Thursday Last Week) Upgrade DOMAIN HOLDINGS AUSTRALIA LI...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

ASX health stocks flat for week in line while broader markets rise of 0.5% Nanosonics has risen ~17% in the past five days on its FY24 result Mach7 falls falls as investing in growth plans push out profit expectations    Healthcare and li...

Stockhead joins with IR Department and Morgans for HealthInvest 2024 in Sydney in September Event to highlight some of ASX’s leading up-and-coming health and life sciences companies Clarity Pharmaceuticals, Percheron Therapeutics, Imricor,...

ASX health stocks rise 0.9% in past five days as broader markets lift 1.2%, despite Friday selloff ImpediMed’s latest quarterly result shows sales momentum building for Sozo device  Cold-cathode X-ray machine developer MicroX makes progres...

The ASX200 had a strong start to the week rising 0.86% to 7989.60 points – not far off the recently hit 8000 level. Investors are anticipating the release of key Australian inflation data on Wednesday. The US Federal Reserve also makes a...

ASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital raises remain a theme for 2024 among healthcare stocks Pharmaceutical distributor EBOS increases stake in MedAdvisor to 9.8% Healthcare and...

Echo IQ is awaiting FDA approval for its AI-powered EchoSolv platform EchoSolv utilises machine learning algorithms to detect aortic stenosis Stockhead reached out to Echo IQ’s COO, Deon Strydom   When looking at a healthcare stock to buy...

In 2024 several ASX medtech companies have upcoming catalysts as they strive to innovate healthcare  Primary results of EBR’s SOLVE trial expected to be published in a leading peer reviewed journal in coming months ImpediMed is focusing in...

ASX health stock fall in past five days in line with broader markets as economic and geopolitical factors weigh heavily ResMed falls as Eli Lily reports positive Phase 3 results of weight-loss drug in obese people with obstructive sleep ap...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.091% to 7,605.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spot...

Provaris Energy has seen its directors strongly support its recent placement  Greentech Metals executive director sees bear lithium market as chance to buy up New board directors of ImpediMed show their confidence in growth prospects of bi...

New ImpediMed leadership team and board committed to company’s success  Private payor and Medicare coverage for SOZO device reaches critical mass in 16 US states ImpediMed prioritises 11 US states for growth as looks to boost sales and ach...

ASX health sector lifts in line with broader markets as reporting season comes to end Morgans upgrades Polynovo as total revenue rises 65.6% on pcp to $48.8 million  Nanosonics cites hospital budgetary pressures as deferring purchasing dec...

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ABG)) - Abacus Group ((ABC)) - Adbri ((AHL)) - Adrad ((AMX)) - Aerometrex ((ALU)) - Altium ((AWC)) - Alumina Ltd ((ATG)) - Articore Group ((ANG)) - Austin Engineering ((...

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

ASX health sector up in line with broader market but some names ail after quarterly results Cochlear lifts net profit guidance for FY24 after stronger than expected first half sales revenue  CSL to report half year results next week with b...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

After early gains, ASX200 finished off the day pretty even – up only .13 of a per cent.  Energy stocks led the gainers, up 1.4 per cent, fuelled by news the Organisation of Petroleum Exporting Countries (OPEC) is looking to cut output to...

Two ASX All Ords shares announced significant changes among their top brass today. And investors reacted by hitting the sell button. While the All Ordinaries Index (ASX: XAO) is up 0.2% at the time of writing, both All Ords shares are in t...

ASX to open higher on Monday after Wall Street’s third straight weekly gains ChargePoint tumbled -35pc, while GAP surged over 30pc And which are the most innovative companies in the world?   Aussie shares are poised to open higher on Mond...